Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EuVichol

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

- PMLiVE

FDA panel backs Puma’s breast cancer drug, with reservations

Side effects concerns could see medicines limited

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

- PMLiVE

Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Analysts predict it will bring in sales of around $600m by 2020

- PMLiVE

Gottlieb heading to FDA after clearing Senate vote

Trump’s favoured candidate received bipartisan support despite criticism

- PMLiVE

FDA clears new ALS drug Radicava ahead of schedule

MT Pharma’s medicine will soon offer US patients an alternative to Sanofi’s Rilutek

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links